Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022)

Revolution Medicines' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $5.4 million for Q3 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 44.02% year-over-year to $5.4 million in Q3 2022; TTM through Sep 2022 was $5.4 million, a 44.02% decrease from a year earlier, with the FY2021 full-year figure at $6.6 million, down 22.5% from the prior year.
• Non-Current Deffered Revenue improved to $5.4 million in Q3 2022 per RVMD's latest filing, from $3.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $12.4 million in Q1 2020 and bottomed at $1.7 million in Q4 2019.
• The 4-year median for Non-Current Deffered Revenue is $7.9 million (2021), against an average of $7.6 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 387.13% in 2020 and plunged 49.65% in 2022, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.7 million in 2019, then soared by 387.13% to $8.5 million in 2020, then retreated by 22.5% to $6.6 million in 2021, then retreated by 17.57% to $5.4 million in 2022.
• Per Business Quant, the three latest RVMD Non-Current Deffered Revenue figures stand at $5.4 million (Q3 2022), $3.8 million (Q2 2022), and $5.7 million (Q1 2022).